Eye injection for diabetic macular edema
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have type 1 or type 2 diabetes.
- You must have vision loss caused by diabetic macular edema (swelling in the back of the eye).
- The swelling in your eye must be confirmed by a special scan (OCT).
- You can be new to treatment or have had treatment before, though the number of previously treated people is limited.
- No stroke or heart attack in the last 6 months.
- No eye surgery (like cataract surgery) in the last 90 days before screening.
- No uncontrolled glaucoma or high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial tests whether combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than the injection alone for people with diabetic macular edema who haven't been treated yet. It aims to improve vision and reduce retinal swelling.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.